Lidocain-Human Teva (Lidocaine Hydrochloride)

Lidocain-Human Teva is a local anesthetic used in musculoskeletal and cardiovascular procedures.

• Intra‑articular procedures: provides local anesthesia to facilitate joint surgery or diagnostic arthroscopy.
• Peri‑articular infiltration: reduces postoperative pain after orthopedic surgery.
• Intravenous administration: offers rapid analgesia and can be employed in anti‑arrhythmic therapy.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel and preventing depolarization. This inhibition stops the propagation of action potentials, thereby interrupting the transmission of pain signals from the site of administration to the central nervous system.

Lidocain-Human Teva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Burning or tingling at the injection site
• Mild dizziness or light‑headedness
• Nausea or metallic taste
• Transient hypotension
• Localized swelling or erythema

Serious or Rare Side Effects

• Systemic toxicity presenting as seizures, cardiac arrhythmias, or respiratory depression
• Allergic reactions including urticaria, angioedema, or anaphylaxis
• Methemoglobinemia, especially with high cumulative doses
• Persistent neurologic deficits (rare)
• Severe hypotension or cardiovascular collapse

Before using Lidocain-Human Teva, clinicians should consider several safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular monitoring: observe for signs of toxicity, especially with high or rapid doses.
• Hepatic impairment: adjust dose or monitor plasma levels due to reduced metabolism.
• Concomitant CNS depressants: use with caution to avoid additive sedation.
• Elderly patients: consider reduced clearance and lower dosing.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocain-Human Teva can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma concentrations.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure.
• Co‑administration with other local anesthetics: additive risk of systemic toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may potentiate cardiac depressant effects.
• Diuretics: can alter plasma protein binding and increase free lidocaine.
• General anesthetics (e.g., propofol, volatile agents): synergistic CNS depression may occur.